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Abstract. In this paper we report that the integrin
complex alphal/betal, a laminin/collagen receptor, is
expressed on cultured foreskin microvascular endothe-
lium, but is absent on endothelial cells from large ves-
sels such as the aorta and umbilical and femoral veins.
The restricted expression of integrin alphal/betal to
microvascular endothelium was also demonstrated in
vivo, by immunohistochemical staining of human tis-
sue sections. Alphal specific antibodies reacted strongly
with endothelial cells of small blood vessels and capil-
laries in several tissues, but not with endothelium of
vein and arteries of umbilical cord. Expression of in-
tegrin alphal can be induced in cultured umbilical vein
endothelial cells by treatment with 5 ng/ml tumor nec-
rosis factor alpha (TNFalpha). Induction of alphal
NDOTHELIALcellsformacontinuouslayer covering the
blood vessel luminal surface and represent the physi-
cal barrier between the blood stream and tissues. The
mechanical and functional integrity ofthis barrier is assured
by interactions amongendothelial cellsas well as by theirad-
hesion to the basal membrane, an extracellular matrix struc-
ture consisting predominantly of collagen type IV, laminin,
nidogen, and heparansulphate. The interaction of endothelial
cells with the basal lamina components is mediated by spe-
cific cell surface receptors belonging to the integrin family.
Integrins are a class of glycoprotein heterodimers of alpha
and beta subunits spanning the plasma membrane and con-
necting the extracellular matrix framework to the intracellu-
lar cytoskeletal structures (Ruoslahti and Pierschbacher,
1987; Hynes, 1987; Hemler, 1990). Endothelial cells from
umbilical vein have been shown to express several integrin
complexes at their surface. These include the fibronectin re-
ceptor (alphal/betal) (Conforti et al ., 1989), the vitronectin
receptor (alpha/beta3) (Cheresh, 1987; Charo et al., 1987;
Dejana et al., 1988; Albelda et al., 1990; Throne et al.,
1990), as well as three other complexes that function as col-
lagen and laminin receptors (alpha2/betal, alphal/betal, and
alpha6/betal) (Albelda et al., 1989; Languino et al., 1989;
Throne et al ., 1990). All five integrin complexes are simul-
taneously expressed by umbilical vein endothelium, endow-
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subunit expression also occurred after treatment of
umbilical vein endothelium with 10-5 M retinoic acid
or with 10 nM PMA; Maximal induction of alphal in-
tegrin was reached after 48 h of treatment and costimu-
lation with TNFalpha and PMA resulted in a synergis-
tic effect. The induction of alphal integrin changed the
adhesive properties of umbilical vein endothelial cells,
by increasing the adhesiveness to collagen, laminin,
and laminin fragment PI, while adhesion to fibronectin
and laminin fragment E8 remained constant. The al-
phal integrin is thus a marker of a specific population
of endothelial cells and its expression confers distinc-
tive properties of interaction with the underlying basal
membrane.
ing these cells with the ability to recognize and adhere to
both basal membrane and stromal matrix components. Anal-
ysis of umbilical vein endothelial cells exposed to several
different inflammatory cytokines and growth factors showed
that tumor necrosis factor alpha (TNFalpha)t and interferon
gamma (IFNgamma) induce a selective downregulation of
specific integrin complexes (Defilippi et al., 1991), thus indi-
cating that endothelial cells can modulate the integrin profile
depending on their functional state.
In this study we show that endothelial cells from different
types of blood vessels express different integrin patterns,
both in vitro and in vivo. In particular, alphal/betal integrin,
known to bind both laminin and collagens, is selectively ex-
pressed on endothelial cells from microvasculature, and not
on endothelial cells from large vessels such as the aorta and
femoral and umbilical veins. Moreover, endothelium from
umbilical vein can express integrin alphal/betal when ex-
posed to TNFalpha, retinoic acid, or PMA. The restricted
expression of alphal/betal complex and its induction by
TNFalpha suggests a specific role of this integrin in endo-
thelial cell function.
1. Abbreviations used in this paper: EC, endothelial cells; FN-R, human
fibronectin receptor; IFNgamma, interferongamma; PAP, peroxidase anti-
peroxidase; TNFalpha, honor necrosis factor alpha.
855Figure 1 . Immunoprecipita-
tion of integrins from micro-
vascular and umbilical EC.
Confluent cultures of micro-
vascular EC and umbilical
vein EC were labeled with
[3sS]methionine for 15 h .
Cells were detergent extracted
and subjected to immunopre-
cipitation with integrin anti-
bodies . (A) Umbilical vein
(lane a) and microvascularEC
(lane b) were immunoprecipi-
tated with FN-R antibodies.
(B) Microvascular EC and
(C) umbilical vein EC were
immunoprecipitated with an-
tibodies specific for the differ-
ent alpha subunits . Lanes a,
alphal monoclonal antibody
TS2/7; lane b, alpha2 mono
clonal antibody 1OGll; lanes c, alpha3 polyclonal antibody ; lanes d, alphas polyclonal antibody ; lanes e, alpha6 monoclonal antibody
GOH3 ; lanesf alpha monoclonal antibody NKI-M9. The radioactive antigens were separated by 6% SDS-PAGE in nonreducing condi-
tions and visualized by fluorography . Arrowheads indicate the position of the alphal subunit . Note the absence of alphal in A, lane a and
C, lane a . Asterisks indicate the immature forms of the beta and alpha subunits as determined by previous pulse-chase experiments .
MaterialsandMethods
Cell Cultureand Treatments
Endothelial cells (EC, were isolated by collagenase (Boehringer Mann-
heim GmBH, Mannheim, Germany) treatment from human umbilical vein
according to the method of Gimbrone (1976) . Cells pooled from three to
sixcords were cultured on gelatin coated90mm plastictissue culture dishes
(Falcon Labware, Oxnard, CA), in medium 199 (Flow Laboratories, Irvine,
Ayrshire, Scotland) supplementedwith 20% FCS (Flow Laboratories), 100
pg/ml bovine brain extract, 100 14g/ml porcine heparin (Sigma Chemical
Co., St . Louis, MO), 100 U/ml penicillin, and 100 Wg/ml streptomycin .
The cells were used for the experiments between passages 2 and 6. Human
foreskin microvascular EC were isolated as described by Davison et al .
(1980) and cultured on fibronectin coated dishes in medium 199 sup-
plemented with 20% human serum, 20 mM Hepes, and penicillin/strep-
tomycin . Primary cultures were incubated for 4h with Dil (3,3'-dioctadecyl-
indocarbocyanine)-labeled acetylated LDL, subsequently detached from
the dish and separated by fluorescence activated cell sorting, as described
by Voyta etal . (1984) . After purification the cells were propagated on gela-
tin coated dishes in M199 medium with 10% human serum, 10% newborn
calfserum, 150,ug/ml bovine brain extract, and 100 Wg/ml porcineheparin,
20mM Hepes, penicillin, and streptomycin . The medium was replaced ev-
ery 2-3 d . At confluence the cells were divided with a split ratio 1:2 .5 . The
cells were characterized for the presence ofvon Willebrandfactor, the bind-
ing ofUlex europeus lectin I, the binding of the endothelium-specific mono-
clonal antibody Pal-E and the uptake of DiI-acetylated LDL, as previously
described (van Hinsberg et al ., 1987a) . Confluent cells between passages
7 and 11 were used for the experiments. Endothelial cells from human aorta
andfemoral vein were isolatedas previously described (van Hinsberg et al .,
1987b) . They were grown on gelatin coated dishes in the same medium as
given above . Confluent cells at passage 8 were used for the experiments .
Treatments with the mediators were performed on confluent cultures .
Human recombinant tumor necrosis factor alpha (TNFalpha) (1Os cyto-
toxic U/mg), was a kind gift from Dr. M . Brockhaus (Hoffmann La Roche,
Basel, Switzerland) . Human recombinant interferon gamma (IFNgamma)
(1Os IU/mg), a kind gift from Dr. G . Garotta (Hoffmann La Roche, Basel,
Switzerland), was used at 100 IU/ml . Human recombinant interleukin 6
(IL-6) (2 x 108 IU/mg), a kind gift from Dr. J. Content (Institut Pasteur
du Brabant, Bruxelles, Belgium), was used at5 ng/ml . Human recombinant
IL-bbeta (Immunex Corp ., Seattle, WA) (5 x 10' IU/mg) and granulocyte
colony stimulating factor (G-CSF) (10' IU/mg) (Bachem Feinchemikalien
AG, Bubendorf, Switzerland) were used at 5 ng/ml and 1,000 U/rnl, re-
spectively. Retinoic acid andPMA were from Sigma Chemical Co. During
treatmentthe medium was changed every day. Allthe treatments ofEC were
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performed in medium 199 supplemented with 20% FCS, in the presence
of 5 ng/ml of recombinant basic fibroblast growth factor (bFGF) (Amer-
sham International, Buckinghamshire, England) as trophic factor.
Antibodiesand Immunoprecipitation ofIntegrins
The polyclonal antibody to the human fibronectin receptor (FN-R), was
prepared by immunizing a goat with affinity-purified fibronectin receptor
from human placenta (Pytela et al ., 1985) . The antiserum was previously
characterized and shownto react with both betal and alphas subunits (Con-
forti et al ., 1989 ; Throne et al ., 1990) . Its reactivity with betal allows the
identification of all receptors ofgroup 1 integrins . The polyclonal antisera
to the betal, alpph3, andalphas integrin subunits were prepared inour labo-
ratory by immunizing rabbits against synthetic peptides reproducing amino
acid sequences from the cytoplasmic domains of each subunit . The follow-
ing peptides, obtained from Multiple PeptideSystem (San Diego, CA), were
used : betal, CTTVVNPKYEGK; alpha3, CRIQPSETERLTDDY alphas,
KRSLPYGTAMEKAQLKPPATSDA. Peptides were coupled to hemocya-
nin with glutaraldehyde (approximate peptideto carrier molar ratio of50 :1)
and rabbits were injected with 500 ug ofthe conjugate in complete Freund
adjuvant. Antibodies reacted specifically with the peptide sequence used for
immunization as determined by ELISA assay on peptide-BSA conjugates.
The antibodies were specific to the appropriate subunit and did not show
cross-reaction with other integrin subunits as demonstrated by immunopre-
cipitation assays on different cell lines .
Mouse monoclonal antibodies to human integrin alphal (mAb TS2/7)
and to integrin betal (mAb AIA5) were a kind gift fromDr. Martin Hemler
(Dana-Farber Cancer Institute, Boston, MA) . The monoclonal antibody
NKI-M9 to integrin alphaV subunit, themonoclonalantibody IOGI l to inte-
grin alpha2 and the monoclonal antibody GOH3 to integrin alpha6 subunit
were kind gifts from Dr. A . Sonnenberg (Central Laboratory ofthe Nether-
lands Red Cross, Amsterdam, The Netherlands) . Since the integrin al-
pha/beta complexes are not dissociated under the experimental conditions
used, antibodies, although specific for one subunit, immunoprecipitate both
of them .
Umbilical vein and microvascular EC were grown at confluence, treated
as indicated and metabolically labeled with [33S]methionine or surface la-
beled with i2'I . [3sS]Methionine labeling was performed by overnight incu-
bation in methionine-free medium (Flow Laboratories) with 5 % serumand
40,uC/ml of ["S]methionine (800 Ci/mM ; Amersham International) in the
presence of the mediators . I'll labeling was performed as described previ-
ously (Rossinoet al ., 1990) . Briefly, cells were released from culture dishes
by 5 mM EDTA treatment in PBS and washed three times by centrifugation
with culture medium . Cells were resuspended in PBS containing CaC12
(1 mM) and MgC12 (1 mM) and labeled with 1 MCi of 125 1 in the presence
856of lactoperoxidase (200 14g/nil) and H202 (0.002%) . To analyze integrins
from cell extracts, labeled cells were washed with cold PBS and the cells
were extracted for 20 min at 4°C with 0.5 % Triton X-100 (BDH Chemicals
Ltd ., Essex, England) in 20 mM Tris-HCI pH 7.4, 150mM NaCI (TBS)
with 1 mM CaCI2, 1 MM M9C12, 10 jig/nil leupeptin, 4 Ag/ml pepstatin,
and 0 .1 TIU/ml aprotinin (all from Sigma Chemical Co .) After centrifuga-
tion at 10,000 g for 10 min, extracts were incubated with the specific anti-
bodies for 1 hat 4°C with gentleagitation . Soluble immunocomplexes were
bound to protein A-Sepharose beads (Pharmacia, Uppsala, Sweden) and
recovered by centrifugation . After washing, bound material was eluted by
boiling beads in 1% SDS (Pierce Chemical Co ., Rockford, IL), analyzed
by 6% SDS-PAGE (Laemmli, 1976), and fluorographed (Chamberlain,
1979) .
Immunoperoxidase Procedure
Immunohistochemical stainings were performed using the peroxidase
anti-peroxidase (PAP) procedure (Sternberger et al ., 1970) . Muscle tissue
was obtained by quadricepsbiopsies ofadult subjects with normal histologi-
cal pattern . Umbilical cords were obtained from the delivery room of the
local hospital . Dermis samples were obtained by skin biopsies from volun-
teer healthy donors . Histologically normal parts of brain and kidney were
obtained by surgery from patients with brain or renal cancer and immedi-
ately frozen.
Cryostat sections (7 um) were fixed with acetone for 5 min at -20°C,
and treated with 3 % H202 for 5 min at room temperature to block endoge-
nous peroxidase . Sections were incubated overnight at 4°C with optimal di-
lution of the primary antibody followed by 30 min atroom temperature with
the secondary antibody. Antibodies to synthetic peptides were affinity
purified on BSA-peptide conjugates coupled to Sepharose and used at con-
centrations ranging from 1 to 10 ug/ml . Samples were then incubated with
peroxidase anti-peroxidase complex (SigmaChemical Co .) and the reaction
was developed with diaminobenzidine tetrahydrochloride (0.05%) .
AdhesionAssay
Fibronectinwas purified from human plasmaby affinity chromatography on
gelatin-Sepharose as previously described (Engvall and Ruoslahti, 1977 ;
Throne et al ., 1982) . Laminin from EHS tumor and its cell binding frag-
ments PI and E8 were a kind gift ofDr. R. Timpl (Max Planck Institut fur
Biochemie, Martinsried, Germany) . Collagen type IV was from Sigma
Chemical Co. Adhesion assay was performed as described previously
(Defilippi et al ., 1991) . 96-well microtiter dishes (Costar, Cambridge, MA)
were coated with optimal concentrations of various substrates and post-
coated with BSA (Eurobio, Paris, France) . Cells were released fromculture
dishes by gentle 5 mM EDTA treatment in PBS and plated in serum-free
DMEM medium (Flow Laboratories) on coated wells for different times at
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Figure 2. Immunoprecipitation of
integrins from aorta (A) and femoral
vein (B)EC. Cells were labeled with
[ 35S]methionine for 15 h, extracted
with detergent, and immunoprecipi-
tated with antibodies specific for the
different alpha subunits . Lanes a,
anti-alpha2 ; lanes b, anti-alpha3 ;
lanes c, anti-alpha5 ; lanes d, anti-
alphal ; lanes e, anti-alpha. The ra-
dioactive antigens were separated
by 6% SDS-PAGE in nonreducing
conditions and visualized by fluo-
rography. Antibodies to alpha6 are
missing from this panel . A separate
experiment, however, showed that
the relative amount of alpha6/betal
complex in these two EC types is
comparable to that detected in um-
bilical EC . Asterisks indicate the im-
mature form of the alpha subunit as
determined by previous pulse-chase
experiments .
37°C. Toeliminate the contribution of protein synthesis andsecretion incell
adhesion, cells were pretreated 2 hbefore detachment with the protein syn-
thesis inhibitor cycloheximide (20mM) (Sigma Chemical Co.), and plated
in the adhesion assay in the presence of 1 uM monensin (Sigma Chemical
Co.) and 20uM cycloheximide. Cell adhesion was evaluated by a colorimet-
ric assay for acid phosphatase activity, by modifying the method described
by Connolly et al . (1986) . Adherent cells were washed two times with PBS,
and acidphosphatase activity in each well was measured by incubating cells
for 90min at 37°C, in the presenceof 200 ul of 10 mMp-nitrophenyl phos-
phate (Sigma Chemical Co.), 0.1% Triton X-100, 0.1 M sodium acetate, pH
5.5. The colorimetric reaction was developed by adding 20 ul of 1 NNaOH .
The optical absorbencies at 405 run were read with a Microplate Reader
(BioRad 450; Bio-Rad Laboratories, Richmond, CA) . A preliminary ex-
periment showed that the optical density was linearly correlated with the
number of viable cells.
AlphallBetal Integrin Is Expressedon Microvascular
butNot on Large Vessel Endotheliumin Culture
Integrin complexes of human foreskin microvascular EC
were immunoprecipitated with antibodies to the FN-R
which react predominantly with the betal subunit (Throne et
al ., 1990) . As shown in Fig . 1 A (lane b) these antibodies
precipitate the beta subunit (120 kD) as well as associated
alpha subunits that are resolved in two bands with molecular
masses of 180 and 160M The fourth band of 100 kD repre-
sent an immature form of the betal subunit as determined by
pulse-chase experiments (Defilippi, P ., and G . Throne, un-
published data ; Heino et al., 1989) . The coprecipitation of
alpha subunits with betal antibodies is due to association of
these molecules in noncovalent complexes at the cell surface
(Ruoslahti and Pierschbacher, 1987; Hynes, 1987; Hemler,
1990) . The integrin pattern described above is identical to
that of umbilical vein EC (Fig . 1 A, lane a) except for the
180-kD band which is unique to microvascular EC . This
molecule has a molecular mass corresponding to that of the
alphal subunit (Hemler, 1990) . To more precisely identify
this component, as well as the other alpha subunits that
comigrate in the 160-kD band, antibodies specific for each
known alpha subunit were used . As shown in Fig . 1 B (laneFigures3and4 . (Fig . 3) Immunohistochemical staining of human skeletal muscle tissue sections with antibodies to integrins . Frozen sec-
tions of striated skeletal muscle tissue were incubated with alphal monoclonal antibody TS2/7 (a, b, d, andf), with betal monoclonal
antibody AIA5 (c and e) or with polyclonal antibodies to von Willebrand factor (g), followed by the appropriate secondary antibodies
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858a) the 180-kD subunit is recognized by alphal-specific mono-
clonal antibodies . In addition, microvascular EC also ex-
press alpha2, alpha3, alpha5, alpha6, and alphaV (Fig . 1 B,
lanes bf) . A1phaV subunit associates with beta3 to form the
vitronectin receptor, while the other alphas are all associated
with betal . Preliminary experiments showed that EC do not
express alpha4 subunit and this antibody was thus omitted
from the panels in Fig . 1 .
The use ofalpha subunit specific antibodies confirmed the
absence of alphal subunit from umbilical vein EC (Fig . 1 C,
lane a) . These cells, like microvascular EC, express alpha2,
alpha3, alpha5, alpha6, and alphaV (Fig . 1 C) . Quantitative
differences were detected in the relative amount of alpha3
and alpha6 subunits between the two EC types : while alpha3
is abundant in microvascular EC, it is only poorly expressed
in umbilical vein endothelium ; the opposite is true for
alpha6.
To determine whether the lack ofexpression ofalphal inte-
grin was a property unique to endothelium from umbilical
vein, we also analyzed EC isolated from human aorta and
femoral vein . As shown in Fig . 2, these EC do not express
the alphal subunit and display an integrin pattern similar to
that ofumbilical veinEC . Thus, the lack ofalphal expression
is typical of various large blood vessels.
Alphal Integrin Is Expressed in Microvascular, but Not
in Umbilical Vessel Endothelium In Situ
To test whether the differential expression of alphal integrin
described above was also detectable in situ, we stained fro-
zen human tissue sections with alphal integrin specific anti-
bodies . As shown in Fig. 3 (a, b, d, and f), the antibodies
intensely stained capillaries as well as vessels with larger di-
ameters (50-150 Am) . These structures were also positive
with integrin betal antibodies (Fig . 3, c and e) . In addition
to skeletal muscle (Fig . 3) capillaries and small vessels in
the dermis, kidney, and brain were also positive for both
alphal and betal antibodies .
Different results were obtained with endothelium from
umbilical cord sections . As shown in Fig . 4 (d-g), the en-
dothelial layer of umbilical vein and arteries was negative for
alphal integrin antibodies, while the underlying smooth
muscle cells of the vessel wall were strongly positive. Sim-
ilar sections were also stained with betal antibodies. In
this case, strong positive reaction was visible in the en-
dothelial layer as well as in the underlying smooth muscle
(Fig . 4, a-c) . These data fully confirmed the results ob-
served with in vitro cultured EC .
Figure 5 . Induction ofalphal subunit expression on umbilical vein
EC. Confluent cultures of umbilical veinEC were treated for 72 h
with different mediators, and labeled with [ 3'Slmethionine in the
last 15 h oftreatment . Cells were detergent extracted and subjected
to immunoprecipitation with FN-R polyclonal antibodies . Un-
treated cells (lane a) ; cells treated with : 5 ng/ml TNFalpha (lane
b) ; 100 IU/mlIFNgamma (lane c) ; 5 ng/ml IL-lbeta (lane d) ; 5 ng/
ml IL-6 (lane e) ; 1,000 U/ml G-CSF (lanef) ; 10-s M retinoic acid
(lane g) ; 10 nM PMA (lane h) . The radioactive antigens were sep-
arated by6% SDS-PAGE in nonreducing conditions and visualized
by fluorography . Asterisks indicate immature forms of alpha and
beta subunits .
Umbilical Vein EC ExpressAlphal Integrin When
Exposed to TNFalpha, Retinoic Acid, orPMA
To test whether large vessel endothelium can be induced to
express alphal integrin, umbilical vein EC were exposed to
various treatments in vitro. As shown in Fig. 5 (lane b), ex-
posure of the cells to TNFalpha resulted in synthesis of
alphal subunit . Other inflammatory cytokines and growth
factors, including IL-lbeta, IFNgamma, IL-6, G-CSF, and
bFGF, were inactive (Fig . 5), indicating a rather specific
effect of TNFalpha . When screening several compounds for
their ability to affect alphal integrin expression, we found
that, in addition to TNFalpha, retinoic acid and the tumor
promoter PMA were also active (Fig . 5, lanes g and h) . The
induction of alphal integrin with TNFalpha, retinoic acid or
and thePAP complex . The sections were counterstained with hematoxylin . Note the positive staining with alphal antibody of microvessels
in longitudinal (a) and transverse (b) sections (arrowheads) . Arterioles (d) and venules ( f) were also positive with alphal antibody. Serial
sections of the vessel in d were also stained with betal (e) or von Willebrand (g) antibodies for comparison . Muscle fibers were stained
only with betal antibody (c and e) . Bar, 30 lAm . (Fig . 4) Immunohistochemical staining ofumbilical vein and artery sections with integrin
antibodies . Frozen sections of umbilical cord were incubated with betal polyclonal antibodies (a-c), or with alphal monoclonal antibody
TS2/7 (d-g), followed by the appropriate secondary antibodies and the PAP complex . The sections were counterstained with hematoxylin .
Note the lack of reaction of alphal antibody with EC in the vein (e-g) and in the artery (d) . This is particularly evident by comparison
with sections stained with betal antibodies where EC from both vein (a and b) and artery (c) are strongly stained . Arrowheads point to
the endothelial cell layer. Note that the smooth muscle cells underneath EC and in the underlying layers of the vessel walls are strongly
positive with both alphal and betal antibodies . The lumen of the artery in c and d (asterisks), can be barely appreciated due to the collapsed
vessel walls . Bars : (a, b, and e-g) 45 14m ; (c and d) 30 lim .
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859Figure 6. Kinetics of induction of alphal subunit by TNFalpha in
umbilical veinEC . Umbilical veinEC were treated forthe indicated
times with 5 ng/ml TNFalpha, and labeled with [ASS]methionine in
the last 6 h of treatment . Cells were detergent extracted and im-
munoprecipitated with FN-R antibodies . The radioactive antigens
were separated by 6% SDS-PAGE in nonreducing conditions and
visualized by fluorography . Arrowhead indicates the position of al-
phal subunit . Asterisks indicate immature forms of beta and alpha
subunits .
PMA followed rather slow kinetics as the protein was ap-
preciable at 24 h and reached maximal levels after 48-72 h
of treatment (Fig. 6) . Expression of alphal remained con-
stant in the presence of the mediators for at least 120 h . A
dose-response analysis was performed with the three active
agents at 48 h of treatment . Retinoic acid was used from
10-° to 10-9 M, and the response reached maximal levels at
10-5 M . TNFalpha was used between 0.1 and 50 ng/ml and
the response reached a plateau at 5 ng/ml . PMA was used
at concentrations between 0.5 nM and 1 uM, and the optimal
dose was found to be 10 nM . When PMA was used at con-
centrations above 500nM, a progressive decrease in alphal
induction was observed, without any toxic effect on cell via-
bility, as measured by methionine incorporation in TCA-
precipitable materials . The level of induced alphal subunit
in umbilical vein EC treated with optimal doses of TNFalpha
orPMA, was comparable to that found in microvascularEC.
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Figure 7 . Synergistic induction of alphal subunit. Umbilical vein
EC were treated for 48 h with 1 nM PMA (1), 0.5 ng/ml TNFalpha
(2), 10- 6 M retinoic acid (3), 1 nM PMA plus 0.5 ng/ml TNFal-
pha (4), and 1 nM PMA plus 10- 6 M retinoic acid (5) . The bars
represent the absolute values of the peak area, expressed in arbi-
trary units, obtained by densitometric analysis of the autoradio-
grams.
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Figure 8. Expression of al-
phal subunit on the cell sur-
face. Confluent cultures ofun-
treated umbilical vein EC
(lanes a and c), and ofumbili-
cal vein EC treated for 72 h
with 5 ng/ml TNFalpha (lanes
b and d), were harvested and
labeled with 'III, as indicated
in Materials and Methods .
Labeled cells were detergent
extracted and subjected to im-
munoprecipitation with FN-R.
antibodies panes a and b) or
alphal monoclonal antibody
panes c and d) . Radioactive
antigens were separated by
6% SDS-PAGE in nonreduc
ing conditions andvisualized by fluorography. Arrowhead indicates
the position of the alphal subunit .
Retinoic acid was slightly less potent compared with TNFal-
pha and PMA . To identify a possible cooperation between
the active mediators, combined treatments were tested . As
shown in Fig . 7, when suboptimal doses were used, a syner-
gistic induction of alphal subunit was observed in cells
costimulated withPMA and TNFalpha or PMA and retinoic
acid . The induced alphal subunit was exposed at the cell sur-
face, as indicated by immunoprecipitation of surface iodi-
nated cells (Fig . 8, lanes b and d) .
Alphal Integrin Expression IncreasesAdhesiveness
of Umbilical Vein EC
To test whether the described induction of alphal integrin on
umbilical vein EC has any effect on the adhesive properties
of these cells, adhesion experiments were performed . The
adhesive response ofumbilical vein EC treated for 48 h with
retinoic acid were compared to that of untreated cells . Ret-
inoic acid was chosen to induce alphal, because TNFalpha
and PMA treatments induced modifications of expression of
other integrin complexes, besides alphal, and this could
complicate the interpretation ofthe results (Defilippi, P., and
G. Throne, unpublished data) . As shown in Fig . 9, retinoic
acid-treated EC showed increased adhesion to microtiter
plates coated with collagen IV (a), and laminin (b), while
they retained normal adhesion to fibronectin (d) . When cells
wereplated on laminin fragments Pl and E8, treated cells ad-
hered faster to PI fragment compared to untreated cells,
while they behaved similarly on E8 fragment (Fig . 9 c) .
These data are consistent with the ligand specificity of
alphal/betal integrin (Ignatius and Reichardt, 1988 ; Kramer
and Marks, 1989 ; Rossino et al ., 1990 ; Hall et al ., 1990) .
Discussion
The data reported in this paper show that integrin alphal/
betal is selectively expressed by EC from microvasculature
but not from large blood vessels such as the aorta, femoral
vein, and umbilical arteries and vein. Moreover, the expres-
sion of this integrin can be induced in large vessel endo-
thelium by the inflammatory cytokine TNFalpha as well as
by other selected agents .
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Expression of alphal/betal seems to be a general property
of microvascular endothelium in different tissues . We have
detected positive capillary and microvascular endothelium in
skeletal muscle, foreskin, dermis, brain, and kidney. Alphal
positive capillary endothelium in dermis, brain, and kidney
has also been reported by others (Konter et al ., 1989 ;
McGeer et al ., 1990 ; Korhonen et al ., 1990) . The strong
staining of microvascular endothelium in situ also excluded
the possibility that synthesis and expression of alphal subunit
in cultured microvascularEC was due to artifacts or contam-
ination of cell culture . At the same time, lack of alphal inte-
grin on EC from large vessels also seems to be a general
property. Negative results were obtained on cultured cells
from aorta, femoral vein and umbilical vein, and absence of
alphal in both arteries and veins was confirmed by tissue
staining of the blood vessels in the umbilical cord . Thus our
results demonstrate that alphal/betal integrin clearly labels
only EC in microvasculature .
The absence of alphal/betal complex in large vessel EC
is not a constitutive property, since we show that different
mediators can induce alphal integrin expression in umbilical
vein EC . Among those tested, the inflammatory cytokine
TNFalpha, the tumor-promoter PMA, and retinoic acid
were found to be active . Retinoic acid is a naturally occur-
ring morphogen involved in tissue differentiation and pattern
formation during vertebrate development (Brockees, 1989) .
It is thus possible that retinoic acid affects endothelial cell
function during development and its ability to induce alphal
integrin in these cells should probably be considered in the
context of its morphogenic activity. Retinoic acid was also
found to induce increased expression of alphal integrin in
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Figure 9 . Kinetics of adhesion of untreated and retinoic acid treated umbilical vein EC to matrix proteins . Untreated umbilical vein EC
(",A) and umbilical veinEC treated with 10-5 M retinoic acid for 72 h (o,o), were incubated in serum free medium at 37°C for different
lengths of time on dishes coated with : (a) 0.5 14g/ml collagen IV; (b) 6 p,g/ml laminin ; (c) 2 ug/ml laminin fragment Pl (",o), 5 jg/ml
laminin fragment E8 (A,o) ; (d) 3 ug/ml fibronectin . At the indicated times, adherent cells were washed two times with PBS, and the num-
berofcells was determined by assaying the acid phosphatase activity (see Materials and Methods) . Each point is a mean value of a triplicate.
neuroblastoma and teratocarcinoma cell lines (Rossino, P.,
andG. Throne, unpublished results), thus indicating that this
integrin alpha subunit is upregulated by retinoic acid in sev-
eral cell types .
A second stimulus for alphal subunit induction is TNFal-
pha, a well characterized cytokine that causes several bio-
chemical and morphological changes in EC in response to
inflammatory stimuli (Pober, 1988) . In particular TNFalpha
increases expression of class I histocompatibility antigens
(Collins et al ., 1986 ; Lapierre et al ., 1988) and of three
adhesive proteins, ICAM-1 (Pober et al ., 1986), ELAM-1
(Pober et al ., 1986 ; Bevilacqua et al ., 1987), and VCAM-1
(Osborn et al ., 1989) . The modulation of the latter proteins
and of alphal integrin by TNFalpha differs by several
criteria . Maximal levels of alphal integrin are reached after
48 h of TNFalpha treatment, while maximal expression of
ICAM-1 andVCAM-1 occurs within 20 h (Pober et al ., 1986 ;
Osborn et al ., 1989) and within 6 h for ELAM-1 (Pober et
al ., 1986 ; Bevilacqua et al ., 1987) . Furthermore, induction
ofELAM-1 is transient as the levels ofthe molecule decline
after 6-8 h of exposure to TNFalpha despite the continuous
presence of the cytokine, while the alphal subunit remains
constant over the time period measured (120 h) . The kinetics
of induction of alphal integrin is comparable to that ob-
served for the induction of class I major histocompatibility
antigens (Collins et al ., 1986) and indicates that these two
molecules have a role in later stages of the inflammatory re-
sponse, as compared with ICAM-1, VCAM-1, and ELAM-1 .
The latter three molecules are located at the apical surface
ofendothelial cell, and mediate adhesion ofleukocytes to the
vessel wall at inflammatory sites. The alphal/betal integrinis likely to be located on the basal surface of the cells to
mediate interaction with basal lamina.
The pathway of intracellular signaling that leads to modu-
lation of alphal integrin expression is likely to involve activa-
tion of protein kinase C (Castagna et al., 1982; Nishizuka,
1984). This is suggested by the fact that low doses of PMA
(10 nM), known to activate protein kinase C (Nishizuka,
1984), induce the expression of alphal integrin. The activa-
tion of protein kinase C has been implicated in the signal
transduction by TNFalpha in several cell types (Johnson and
Baglioni, 1990; Schutze et al., 1990). In line with this we
found that PMA potentiates the effect ofTNFalpha on alphal
induction, when the two agents are administered simultane-
ously. Furthermore, treatment of umbilical vein EC with
dosesof PMA above 500 nM, known to deplete cellsofpro-
tein kinase C activity (Adams and Gullick, 1989), results in
a decreased level of induction of alphal integrin.
We have previously shown that treatment of umbilical vein
EC with a combination of both TNFalpha and IFNgamma
alters the expression of the vitronectin receptor (integrin
beta3) (Throne et al., 1990; Defilippi et al., 1991). In this
case the two cytokines caused a downregulation of this
receptor by specifically affecting the synthesis of the beta3
subunit. A third integrin complex, alpha6/betal, is down-
regulated by TNFalpha (Defilippi, P , and G. Throne, unpub-
lished results), thus showing that alteration of the en-
dothelium-matrix interactions is likely to play an important
role in the vascular response during inflammation.
Integrin alphal/betal is expressed on several cell types and
binds both collagens and laminin (Ignatius and Reichardt,
1988 ; Kramer and Marks, 1989; Turner et al ., 1989; Ros-
sino et al., 1990; Hall et al., 1990) . Recently Kramer et al.
(1990) reported the expression of alphal/betal integrin in
microvascular EC and showed that this receptor can bind
laminin. Moreover, previous data indicate that the interac-
tion of EC with laminin and collagens involves multiple
receptors, including alpha2/betal, alpha3/betal, alpha6/
betal, and alpha/beta3 (Languino et al., 1989 ; Kramer et
al., 1990), and the precise role of each of them is not yet de-
termined. An interesting functional property of the alphal/
betal integrin is its ability to bind to a laminin region distinct
from that recognized by other integrin complexes. Laminin
structure has been extensively investigated using the protein
produced by the mouse EHS tumor. This protein is a cross-
shaped molecule of 900 kD, consisting of three polypeptide
chains, A, Bl, and B2 (Timpl, 1989), and can be split into
two major fragments by proteolysis. These are the E8 frag-
ment, obtained by elastase digestion and corresponding to
the lower portion of the long arm of the cross (Paulsson et
al ., 1985), and the Pl, or El, fragment, obtained by either
pepsin or elastase digestion, and corresponding to the cen-
tral region of the molecule at the junction of the three short
arms (Timpl, 1989). The three laminin receptors, alpha2/
betal, alpha3/betal, and alpha6/betal all bind to the long
arm region (Fragment E8) (Languino, L., and E. Ruoslahti,
personal communication; Gehlsen et al., 1989; Sonnenberg
et al., 1990; Hall et al., 1990), whilethe binding site of the
recently identified laminin binding alpha/beta3 complex
(Kramer et al., 1990) has not yet been mapped. The alphal/
betal receptor, on the other hand, binds to the central cross
region of laminin (PI fragment) (Hall et al ., 1990; Rossino
et al., 1990). In agreement with the binding specificity, we
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found that expression of alphal integrin on umbilical vein
EC, potentiates the adhesion ofEC to collagen, laminin, and
laminin fragment P1, but not to laminin fragment E8 or to
fibronectin. It is also possible that the alphal/betal receptor
recognizes a specific laminin isoform different from the A,
BI, B2 molecule used in our experiments. In fact, in addition
to the mouse EHS laminin, different isoforms of the mole-
cule have been described, with distinct subunit composition
and tissue distribution (Edgar et al ., 1988; Leivo and Eng-
vall, 1988; Hunter et al ., 1989) . These isoforms, however,
are not yet available in pure form for experimental test.
The adhesive behavior of alphal-expressing EC may be
functionally important under specific circumstances, such as
angiogenesis (new blood vessel formation) . TNFalpha and
PMA, that induce alphal expression, were also found to
stimulate angiogenesis in an in vitro assay where endothelial
cells are induced to penetrate a three-dimensional collagen
gel (Leibovichet al., 1987; Montesano and Orci, 1987). An-
giogenetic stimuli should induce several biochemical changes
in endothelium, including proliferation, cytoskeletal assem-
bly and protease secretion. During this process, EC should
switch from a stationary to a migratory behavior and it is
quite likely that such transition in adhesive properties re-
quires changes of integrin expression such as those described
here and in previous work (Defilippi et al ., 1991) .
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